Ashland advances strategic $60MM network optimization
Ashland (NYSE: ASH) has provided an update on its $60 million manufacturing network optimization plan, announcing significant facility changes and strategic consolidations. The company will close its Parlin, New Jersey facility and transfer hydroxyethyl cellulose (HEC) production to Hopewell, Virginia. Additionally, Ashland will close its Chatham, New Jersey plant and move microbial protection production to Freetown, Massachusetts.
The optimization plan follows the completion of a $30 million restructuring initiative and includes major investments in facilities across the United States, Europe, China, Brazil, and India. The company is strengthening its core technologies, including vinyl pyrrolidone and derivatives (VP&D) and HEC, while expanding its global manufacturing footprint for injectables, tablet coatings, and biofunctionals businesses.
Ashland (NYSE: ASH) ha fornito un aggiornamento sul suo piano di ottimizzazione della rete produttiva da 60 milioni di dollari, annunciando importanti modifiche agli stabilimenti e consolidamenti strategici. L'azienda chiuderà lo stabilimento di Parlin, New Jersey, trasferendo la produzione di idrossietilcellulosa (HEC) a Hopewell, Virginia. Inoltre, Ashland chiuderà lo stabilimento di Chatham, New Jersey, spostando la produzione di protezione microbica a Freetown, Massachusetts.
Il piano di ottimizzazione segue il completamento di un programma di ristrutturazione da 30 milioni di dollari e prevede investimenti significativi in impianti negli Stati Uniti, Europa, Cina, Brasile e India. L'azienda sta rafforzando le sue tecnologie chiave, tra cui il vinylpyrrolidone e i suoi derivati (VP&D) e l'HEC, espandendo al contempo la propria presenza produttiva globale per i settori degli iniettabili, dei rivestimenti per compresse e dei biofunzionali.
Ashland (NYSE: ASH) ha proporcionado una actualización sobre su plan de optimización de la red de fabricación de 60 millones de dólares, anunciando cambios significativos en las instalaciones y consolidaciones estratégicas. La compañía cerrará su planta en Parlin, Nueva Jersey, y trasladará la producción de hidroxietilcelulosa (HEC) a Hopewell, Virginia. Además, Ashland cerrará su planta en Chatham, Nueva Jersey, y moverá la producción de protección microbiana a Freetown, Massachusetts.
El plan de optimización sigue a la finalización de una iniciativa de reestructuración de 30 millones de dólares e incluye importantes inversiones en instalaciones en Estados Unidos, Europa, China, Brasil e India. La empresa está fortaleciendo sus tecnologías clave, incluyendo el polivinilpirrolidona y sus derivados (VP&D) y HEC, mientras expande su presencia manufacturera global para los negocios de inyectables, recubrimientos de tabletas y biofuncionales.
Ashland (NYSE: ASH)는 6,000만 달러 규모의 제조 네트워크 최적화 계획에 대한 업데이트를 제공하며 주요 시설 변화와 전략적 통합을 발표했습니다. 회사는 뉴저지주 파를린 공장을 폐쇄하고 하이드록시에틸셀룰로오스(HEC) 생산을 버지니아주 호프웰로 이전할 예정입니다. 또한, 애슐랜드는 뉴저지주 채텀 공장을 폐쇄하고 미생물 보호 생산을 매사추세츠주 프리타운으로 이전합니다.
이번 최적화 계획은 3,000만 달러 규모의 구조조정 이니셔티브 완료에 따른 것으로, 미국, 유럽, 중국, 브라질, 인도 전역의 시설에 대한 대규모 투자를 포함합니다. 회사는 비닐피롤리돈 및 그 파생물(VP&D), HEC 등 핵심 기술을 강화하는 한편, 주사제, 정제 코팅, 바이오펑셔널 사업을 위한 글로벌 제조 기반을 확장하고 있습니다.
Ashland (NYSE : ASH) a fourni une mise à jour de son plan d'optimisation du réseau de production de 60 millions de dollars, annonçant des changements significatifs dans ses installations et des consolidations stratégiques. L'entreprise va fermer son site de Parlin, New Jersey, et transférer la production d'hydroxyéthylcellulose (HEC) à Hopewell, Virginie. De plus, Ashland fermera son usine de Chatham, New Jersey, et déplacera la production de protection microbienne à Freetown, Massachusetts.
Ce plan d'optimisation fait suite à la finalisation d'une initiative de restructuration de 30 millions de dollars et comprend d'importants investissements dans des installations aux États-Unis, en Europe, en Chine, au Brésil et en Inde. L'entreprise renforce ses technologies clés, notamment le pyrrolidone de vinyle et ses dérivés (VP&D) ainsi que l'HEC, tout en étendant sa présence mondiale dans la fabrication pour les secteurs des injectables, des enrobages de comprimés et des biofonctionnels.
Ashland (NYSE: ASH) hat ein Update zu seinem 60-Millionen-Dollar-Plan zur Optimierung des Fertigungsnetzwerks veröffentlicht und bedeutende Änderungen an den Anlagen sowie strategische Konsolidierungen angekündigt. Das Unternehmen wird seine Anlage in Parlin, New Jersey, schließen und die Produktion von Hydroxyethylcellulose (HEC) nach Hopewell, Virginia, verlagern. Zudem wird Ashland sein Werk in Chatham, New Jersey, schließen und die Produktion von mikrobiellen Schutzmitteln nach Freetown, Massachusetts, verlegen.
Der Optimierungsplan folgt auf den Abschluss einer 30-Millionen-Dollar-Restrukturierungsinitiative und umfasst umfangreiche Investitionen in Anlagen in den USA, Europa, China, Brasilien und Indien. Das Unternehmen stärkt seine Kerntechnologien, darunter Vinylpyrrolidon und Derivate (VP&D) sowie HEC, und erweitert gleichzeitig seine globale Produktionsbasis für Injektionsmittel, Tablettenbeschichtungen und Biofunktionalprodukte.
- Strategic $60 million network optimization to enhance operational efficiency and profitability
- Consolidation of smaller plants into larger manufacturing sites for improved cost structure
- Global expansion with investments in Ireland, USA, Brazil, China, and India
- Development of new patented technologies with market expansion potential
- Closure of manufacturing facilities in Parlin and Chatham, New Jersey
- Significant capital expenditure required for facility transfers and expansions
Insights
Ashland's $60M network optimization strengthens competitiveness through strategic plant closures and consolidation, enhancing profitability while supporting growth initiatives.
Ashland's $60 million manufacturing network optimization represents a calculated approach to improving operational efficiency and cost position. The closure of the Parlin and Chatham facilities in New Jersey, with production transfers to Hopewell, Virginia and Freetown, Massachusetts respectively, demonstrates a deliberate consolidation strategy to achieve economies of scale at larger manufacturing sites.
The optimization of hydroxyethyl cellulose (HEC) production is particularly significant, as it completes a critical component of the broader savings initiative. By concentrating HEC manufacturing at plants in the US, Europe, and China, Ashland creates a more resilient supply network while reducing overhead costs. The Hopewell facility's expanded role indicates a shift toward manufacturing centers of excellence, which typically yield 15-20
Beyond the
The global investment strategy across Ireland, Brazil, China, India, and domestic facilities indicates a balanced approach to manufacturing footprint optimization—simultaneously reducing costs while strategically positioning production capabilities in high-growth markets. This calibrated consolidation enables Ashland to improve profit margins while maintaining the production flexibility needed to support their innovation-driven growth strategy.
WILMINGTON, Del., July 08, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today provided an update on its
"Our team has been focused on a deliberate strategy, taking purposeful actions to increase our competitive position," said Guillermo Novo, chair and chief executive officer, Ashland. "With the completion of our portfolio optimization and
The company's
Novo emphasized, “These decisive actions allow us to navigate near-term challenges effectively and position Ashland for enhanced profitability and operating consistency. It's about acting with prudence and discipline, concentrating on our controllable factors to maximize results and deliver on our self-help growth commitments."
Under its "globalize" strategy, Ashland has made significant investments in Ireland and the United States for its injectables business, in Brazil for its tablet coatings and microbial protection business, in China for its biofunctionals actives business, and in the United States and Europe for microbial protection. The company is also in the process of building a tablet coating plant in India.
During a recent Innovation Day for analysts and investors, Ashland showcased enhanced capabilities and expanded applications of its scalable technology platforms. These new-to-the-world, patented technologies can be "tuned" and precisely calibrated for customer and regional preferences, environmental conditions and regulatory considerations, allowing Ashland to unlock new, sizable markets with differentiated performance.
“Ashland's strategic priorities represent a fundamental shift in how we approach innovation, organic growth, and manufacturing," Novo added. "The portfolio and network optimization efforts provide strategic flexibility for the cost-effective repurposing of assets. This enables de-risked production for our new technology platforms, while combining the efficiency of large-scale operations with the precision of localized customization to serve our customers.”
About Ashland
Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, personal care and pharmaceutical. Approximately 2,960 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as “anticipates,” “believes,” “expects,” “estimates,” “is likely,” “predicts,” “projects,” “forecasts,” “objectives,” “may,” “will,” “should,” “plans” and “intends” and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its annual reports, quarterly reports and other filings with the SEC, news releases and other written and oral communications. These forward-looking statements are based on Ashland’s expectations and assumptions, as of the date such statements are made, regarding Ashland’s future operating performance, financial, operating cash flow and liquidity, as well as the economy and other future events or circumstances. These statements include but may not be limited to statements with respect to Ashland’s expectations regarding its manufacturing network optimization plan.
Ashland’s expectations and assumptions include, without limitation, internal forecasts and analyses of current and future market conditions and trends, management plans and strategies, operating efficiencies and economic conditions (such as prices, supply and demand, cost of raw materials, and the ability to recover raw-material cost increases through price increases), and risks and uncertainties affecting Ashland that are described in Ashland’s most recent Form 10-K (including Item 1A Risk Factors) filed with the SEC, which is available on Ashland’s website at http://investor.ashland.com or on the SEC’s website at http://www.sec.gov. Various risks and uncertainties may cause actual results to differ materially from those stated, projected or implied by any forward-looking statements. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update any forward-looking statements made in this news release whether as a result of new information, future events or otherwise.
™ Trademark, Ashland or its subsidiaries, registered in various countries.
FOR FURTHER INFORMATION:
Investor Relations: | Media Relations: |
William C. Whitaker | Carolmarie C. Brown |
+1 (614) 790-2095 | +1 (302) 995-3158 |
wcwhitaker@ashland.com | ccbrown@ashland.com |
Attachment
